Eledon Pharmaceuticals (ELDN) News Today $3.18 +0.14 (+4.43%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELDN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Woodline Partners LP Boosts Stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Woodline Partners LP increased its stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 98.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,671,822 shares of the company's stock after acquiring an additional 828,930 shaMay 26 at 4:37 AM | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Rating Increased to Hold at Wall Street ZenWall Street Zen raised shares of Eledon Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Thursday.May 24 at 11:59 AM | marketbeat.com1,100,473 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Acquired by AWM Investment Company Inc.AWM Investment Company Inc. acquired a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,100,473 shares of the company's stock, valued at approximately $4,534,May 23, 2025 | marketbeat.comEquities Analysts Offer Predictions for ELDN Q2 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Noble Financial issued their Q2 2025 EPS estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Monday, May 19th. Noble Financial analyst R. Leboyer anticipates that the company will earn ($0.22) perMay 23, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Invests $4.85 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Frazier Life Sciences Management L.P. purchased a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,176,735 shares ofMay 23, 2025 | marketbeat.comZimmer Partners LP Has $3.09 Million Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Zimmer Partners LP lessened its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 47.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 750,000 shares of the company's stock after selling 684,727 shares during thMay 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Point72 Asset Management L.P. purchased a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,095,000 shares of the company's stock, valued at approximately $4,511,000. PoMay 22, 2025 | marketbeat.comWhat is Noble Financial's Estimate for ELDN Q2 Earnings?May 22, 2025 | americanbankingnews.comVelan Capital Investment Management LP Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Velan Capital Investment Management LP bought a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 323,973 shares of the companyMay 21, 2025 | marketbeat.comFY2025 EPS Estimates for ELDN Boosted by Cantor FitzgeraldEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Eledon Pharmaceuticals in a report released on Thursday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company wilMay 21, 2025 | marketbeat.comEquities Analysts Issue Forecasts for ELDN FY2025 EarningsMay 20, 2025 | americanbankingnews.comQ2 EPS Estimate for Eledon Pharmaceuticals Lifted by AnalystEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of Eledon Pharmaceuticals in a report issued on Wednesday, May 14th. Leerink Partnrs analyst T. Smith now forecasts that the company willMay 20, 2025 | marketbeat.comLeerink Partnrs Has Optimistic Outlook of ELDN Q2 EarningsMay 20, 2025 | americanbankingnews.comSphera Funds Management LTD. Buys 1,254,298 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Sphera Funds Management LTD. raised its stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 96.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,551,619 sharesMay 18, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on Eledon Pharmaceuticals stockMay 17, 2025 | uk.investing.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Shares Purchased by Ensign Peak Advisors IncEnsign Peak Advisors Inc boosted its holdings in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 185.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,264,919 shares of the company's stockMay 17, 2025 | marketbeat.comEledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial ResultsMay 14, 2025 | globenewswire.comAlyeska Investment Group L.P. Increases Stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Alyeska Investment Group L.P. grew its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 86.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 933,475 shares of the company's stock after buying an additional 433,475 shares during the peMay 8, 2025 | marketbeat.comMarshall Wace LLP Invests $331,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Marshall Wace LLP acquired a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 80,431 shares of the company's stock, valued at approximately $331,000. MarshallMay 7, 2025 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Increase in Short InterestEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,750,000 shares, a growth of 19.9% from the March 31st total of 1,460,000 shares. Approximately 3.3% of the company's stock are short sold. Based on an average daily volume of 233,300 shares, the days-to-cover ratio is currently 7.5 days.May 5, 2025 | marketbeat.comAllostery Investments LP Makes New Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Allostery Investments LP purchased a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 100,000 shares of the coMay 4, 2025 | marketbeat.com683 Capital Management LLC Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)683 Capital Management LLC bought a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 154,960 shares of the company's stock, valued at apprMay 4, 2025 | marketbeat.com235,750 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Acquired by Acuta Capital Partners LLCAcuta Capital Partners LLC acquired a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 235,750 shares of the company's stock, valued at approximMay 4, 2025 | marketbeat.comEledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance SheetMay 3, 2025 | seekingalpha.comRA Capital Management L.P. Acquires New Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)RA Capital Management L.P. bought a new position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,566,338 shares of the company's stock, valueMay 3, 2025 | marketbeat.comEledon Pharmaceuticals (ELDN) to Release Earnings on ThursdayEledon Pharmaceuticals (NASDAQ:ELDN) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-eledon-pharmaceuticals-inc-stock/)May 3, 2025 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has caught the attention of institutional investors who hold a sizeable 46% stakeMay 2, 2025 | finance.yahoo.comBoothbay Fund Management LLC Buys New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Boothbay Fund Management LLC purchased a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 341,923 shares of the company's stock, valuedMay 1, 2025 | marketbeat.comNantahala Capital Management LLC Raises Stock Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Nantahala Capital Management LLC lifted its position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 91.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,147,946 shares of the company's stoApril 30, 2025 | marketbeat.comFirst Light Asset Management LLC Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)First Light Asset Management LLC bought a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,328,768 shares of the company's stock, vaApril 30, 2025 | marketbeat.comGeode Capital Management LLC Buys 285,043 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Geode Capital Management LLC lifted its stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 75.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 663,101 shares of the company's stock after purchasing anApril 30, 2025 | marketbeat.comBlue Owl Capital Holdings LP Takes Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Blue Owl Capital Holdings LP acquired a new position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,959,912 shares of the company's stock, valued at approximately $8,075,000.April 26, 2025 | marketbeat.comEAM Investors LLC Makes New Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)EAM Investors LLC purchased a new stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 109,555 shares of the company's stock, valued atApril 20, 2025 | marketbeat.comIs Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5?March 27, 2025 | uk.finance.yahoo.comCantor Fitzgerald Weighs in on ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Eledon Pharmaceuticals in a research note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the compaMarch 27, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook of ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith now anticipates that the compaMarch 27, 2025 | marketbeat.comEquities Analysts Set Expectations for ELDN Q1 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.28) perMarch 26, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), Eledon Pharmaceuticals (ELDN)March 24, 2025 | markets.businessinsider.comGuggenheim Remains a Buy on Eledon Pharmaceuticals (ELDN)March 24, 2025 | markets.businessinsider.comWe're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash WiselyMarch 22, 2025 | finance.yahoo.comEledon Pharmaceuticals Reports 2024 Financial Results and Clinical AdvancesMarch 22, 2025 | tipranks.comEledon Pharmaceuticals (NASDAQ:ELDN) Posts Earnings Results, Misses Estimates By $0.30 EPSEledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.30).March 21, 2025 | marketbeat.comEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial ResultsMarch 20, 2025 | globenewswire.comEledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 3.4% - Here's WhyEledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.4% - Should You Sell?March 5, 2025 | marketbeat.comEledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare ConferenceMarch 4, 2025 | globenewswire.comLeerink Partnrs Has Pessimistic View of ELDN Q4 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Leerink Partnrs reduced their Q4 2024 earnings estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.32) per shFebruary 10, 2025 | marketbeat.comEledon Pharmaceuticals' Investigational Therapy Tegoprubart Successfully Used in Landmark Kidney Xenotransplant at Mass General Transplant CenterFebruary 9, 2025 | nasdaq.comEledon's tegoprubart used in second pig-to-human kidney transplantFebruary 7, 2025 | msn.comEledon announces tegoprubart use in transplant of pig kidney into humanFebruary 7, 2025 | markets.businessinsider.comEledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a HumanFebruary 7, 2025 | globenewswire.com Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELDN Media Mentions By Week ELDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼1.330.78▲Average Medical News Sentiment ELDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼152▲ELDN Articles Average Week Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NRIX News Today AVXL News Today IMNM News Today RCKT News Today AVBP News Today DAWN News Today TRVI News Today IMTX News Today SION News Today EOLS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELDN) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
